APOE and fatty liver disease: In line with the above findings that the TG levels were reduced in the liver of saringosterol-treated ApoE−/− mice (Figure 2F), histological analysis revealed that saringosterol treatment could attenuate the hepatic steatosis in atherosclerotic ApoE−/− mice (Figure 5A).